Cutler Group LP Geron Corp Call Options Transaction History

Cutler Group LP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Jul 18, 2023	SELL	$1.97 - $3.69 $197 - $369	-100 Reduced 11.11%	800 $0
Q1 2023 May 01, 2023	SELL	$2.14 - $3.4 $3,852 - $6,120	-1,800 Reduced 66.67%	900 $0
Q1 2022 Apr 14, 2022	SELL	$0.99 - $1.6 $99 - $160	-100 Reduced 3.57%	2,700 $0
Q3 2021 Oct 26, 2021	SELL	$1.2 - $1.5 $600 - $750	-500 Reduced 15.15%	2,800 $0
Q2 2021 Jul 19, 2021	SELL	$1.25 - $1.83 $17,750 - $25,986	-14,200 Reduced 81.14%	3,300 $1,000
Q1 2021 Apr 26, 2021	BUY	$1.52 - $2.1 $25,232 - $34,860	16,600 Added 1844.44%	17,500 $2,000
Q1 2020 May 07, 2020	SELL	$0.89 - $1.49 $356 - $596	-400 Reduced 30.77%	900 $0
Q4 2019 Feb 06, 2020	BUY	$1.27 - $1.54 $508 - $616	400 Added 44.44%	1,300 $0
Q4 2018 Feb 05, 2019	SELL	$0.98 - $1.85 $98 - $185	-100 Reduced 10.0%	900 $0
Q3 2018 Nov 07, 2018	BUY	$1.76 - $6.38 $1,760 - $6,380	1,000 New	1,000 $0

274

491M

1.87M

690K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.32B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.